More on RNXT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+12.5% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

RenovoRx (NQ:RNXT)
Delayed: 2.11 +0.18 (9.33%)
Prev. Close $1.93  
Open$1.91 
52 Wk High$ 
52 Wk Low$ 
Day High$2.20 
Day Low$1.83 
P/E N/A  
EPS$ 
Volume3,313,210 

Friends, Peers and Foes (?): CELC, ONCY, OSTX SLS (more...)

Aug 25, 2026 08:31 AM RenovoRx publishes PK/PD data from pancreatic cancer drug trial
Aug 25, 2026 08:30 AM RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Aug 21, 2026 08:30 AM RenovoRx regains Nasdaq minimum bid price compliance
Aug 21, 2026 08:30 AM RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 20, 2026 04:06 PM Form 8-K RenovoRx, Inc. For: Aug 20
Aug 20, 2026 08:30 AM RenovoRx receives USPTO notice of allowance for RenovoCath patent
Aug 20, 2026 08:30 AM RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
Aug 13, 2026 04:13 PM Form 10-Q RenovoRx, Inc. For: Jun 30
Aug 13, 2026 04:08 PM Form 8-K/A RenovoRx, Inc. For: Aug 12
Aug 12, 2026 05:13 PM RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c
View All Articles

Entities mentioned with RNXT

View All Entities